Leukemia, Acute Clinical Trial
Official title:
Pilot Study of a Novel Psychotherapeutic Intervention for Caregivers of Patients With Acute Leukemia: Emotion and Symptom-focused Engagement for Caregivers (EASE-CG)
The purpose of this study is to test the feasibility and acceptability of an adapted psychosocial intervention, called Emotion and Symptom-focused Engagement for Caregivers (EASE-CG), to reduce traumatic stress symptoms and other psychological distress and increase well-being in primary caregivers of patients newly diagnosed with acute leukemia.
Emotion and Symptom-focused Engagement for Caregivers (EASE-CG) is a brief psychotherapeutic intervention designed for primary caregivers of patients newly diagnosed with acute leukemia (AL). The EASE-CG intervention was adapted from a previous psychotherapeutic intervention for adult patients newly diagnosed with AL, called Emotion and Symptom-focused Engagement (EASE). In a previous pilot trial, EASE was associated with reductions in traumatic stress and physical symptom burden in adult patients with AL. EASE-CG is a sub-study of a multi-center, longitudinal, mixed-methods study on the experience of traumatic stress in primary caregivers of patients newly diagnosed with AL within three months of admission to the hospital (Main study). The purpose of this sub-study is to conduct a non-randomized, mixed-methods pilot study to test the feasibility and acceptability of EASE-CG. A subset of caregivers of pediatric patients from the Main study will be approached to participate in EASE-CG. Quantitative measures will be administered at baseline, 1, 3 (primary endpoint), 6, 9, and 12 months (Main study endpoint). Participants may be invited to brief, semi-structured interviews. The study will take place at the Hospital for Sick Children; the largest leukemia treatment center in Canada for pediatric patients. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03680677 -
Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
|
||
| Completed |
NCT04194086 -
Population Pharmacokinetics and Safety of Oral Posaconazole in Children With Leukemia
|
Phase 1/Phase 2 | |
| Completed |
NCT04710212 -
Screening for Colonization With Resistant Enterobacterales in Neutropenic Patients With Hematologic Malignancies
|
||
| Terminated |
NCT01050764 -
Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells
|
Phase 1/Phase 2 | |
| Completed |
NCT03434704 -
Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole
|
Phase 2 | |
| Recruiting |
NCT05823571 -
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
|
Phase 1 | |
| Completed |
NCT04236063 -
Rehabilitation Needs of the Malaysian Haematological Cancer Survivors
|
||
| Completed |
NCT04745416 -
Clinical Characteristics of Patients With Leukemia and COVID-19
|
||
| Not yet recruiting |
NCT03336632 -
Chidamide Plus PTCy/Cyclosporine to Prevent GVHD After Myeloablative Conditioning, Matched PBSCT
|
Phase 2 | |
| Completed |
NCT05969600 -
The Relapses in Childhood Acute Lymphoplastic Leukemia Excluding L3
|
||
| Recruiting |
NCT06335277 -
Total Body Irradiation Treatments for Patients Treated at European Institute of Oncology
|
||
| Recruiting |
NCT03553238 -
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03564470 -
Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03564704 -
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL
|
Phase 2/Phase 3 | |
| Terminated |
NCT03963024 -
Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT
|
Phase 1 | |
| Completed |
NCT04051216 -
The SMART CART Study: Health Information Technology
|
N/A | |
| Completed |
NCT03297476 -
Clinical Application of Novel Panels for Early Precision Diagnosis and Relapse Prediction in High-risk Leukemia
|
||
| Recruiting |
NCT04482894 -
Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS
|
Phase 2 |